Ajanta Pharma Limited (AJANTPHARM) — Announcement | 3 August 2026

· NSE Neutral
By StockFin Research Team AI-Assisted Analysis Source: BSE/NSE Filings
📢 Key Event
Company released written transcript of Q1 FY26 earnings call
💡 Investor Takeaway
Shareholders can review management's detailed commentary on quarterly performance and future outlook.

Ajanta Pharma announced that a written transcript of its Q1 FY26 earnings call held on July 30, 2026, is now available on its website, providing investors access to management commentary on results and forward-looking commentary.

📄 View Original Announcement (PDF)

About Ajanta Pharma Limited (AJANTPHARM)

Healthcare · Pharmaceuticals · Listed on NSE

Market Cap: ₹44,226.59 Cr P/E: 39.0 ROE: 25.1% ROCE: 31.8% Div Yield: 0.79%

View full AJANTPHARM stock details →

📡 Get AI alerts when AJANTPHARM files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track AJANTPHARM — Free

📊 More AJANTPHARM filings

See all AJANTPHARM filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when AJANTPHARM files new disclosures

Track AJANTPHARM filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track AJANTPHARM — Free

Free account · 2 AI queries/day